The USFDA approves a generic medication from Zydus Lifesciences

The US health regulator approved Zydus Lifesciences' application to market a generic medication used to lower triglycerides in the USA.

In a regulatory filing, the company reported that it gained final approval from the US Food and Drug Administration (USFDA) to market Icosapent Ethyl Capsules in strengths of 0.5 g and 1 g.

Adults with severe hypertriglyceridemia can use these capsules in combination with a low fat diet to reduce triglyceride levels.

Icosapent Ethyl Capsules, 0.5 g and 1 g, had annual sales of USD 1,316 million in the US, according to IQVIA. Shares of the company were trading marginally higher at Rs 518.80 apiece on BSE.